Compare Stocks: IMUX, ACHV, COLL, and PHAT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$8.49 +2.2%	$6.93	$2.62 ▼ $8.64	$855.12M	2.25	1.44 million shs	874,073 shs
COLL Collegium Pharmaceutical	$23.53 -0.7%	$31.86	$23.37 ▼ $50.79	$771.58M	0.72	903,689 shs	884,072 shs
IMUX Immunic	$13.11 +2.7%	$14.96	$5.06 ▼ $17.43	$178.87M	1.41	223,897 shs	420,887 shs
PHAT Phathom Pharmaceuticals	$9.50 +5.0%	$10.06	$8.21 ▼ $18.31	$768.56M	0.51	1.20 million shs	1.24 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+2.17%	+4.81%	+27.48%	+65.50%	+196.85%
COLL Collegium Pharmaceutical	-0.72%	-7.18%	-34.15%	-29.51%	-40.57%
IMUX Immunic	+2.74%	-14.87%	-6.10%	+2.66%	+62.92%
PHAT Phathom Pharmaceuticals	+4.97%	+3.49%	+15.43%	-6.22%	-20.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$8.49 +2.2%	$6.93	$2.62 ▼ $8.64	$855.12M	2.25	1.44 million shs	874,073 shs
COLL Collegium Pharmaceutical	$23.53 -0.7%	$31.86	$23.37 ▼ $50.79	$771.58M	0.72	903,689 shs	884,072 shs
IMUX Immunic	$13.11 +2.7%	$14.96	$5.06 ▼ $17.43	$178.87M	1.41	223,897 shs	420,887 shs
PHAT Phathom Pharmaceuticals	$9.50 +5.0%	$10.06	$8.21 ▼ $18.31	$768.56M	0.51	1.20 million shs	1.24 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+2.17%	+4.81%	+27.48%	+65.50%	+196.85%
COLL Collegium Pharmaceutical	-0.72%	-7.18%	-34.15%	-29.51%	-40.57%
IMUX Immunic	+2.74%	-14.87%	-6.10%	+2.66%	+62.92%
PHAT Phathom Pharmaceuticals	+4.97%	+3.49%	+15.43%	-6.22%	-20.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$15.00	76.68% Upside
COLL Collegium Pharmaceutical	2.71	Moderate Buy	$51.00	116.74% Upside
IMUX Immunic	3.00	Buy	$47.25	260.41% Upside
PHAT Phathom Pharmaceuticals	2.88	Moderate Buy	$22.86	140.60% Upside

Current Analyst Ratings Breakdown

Latest IMUX, ACHV, COLL, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	IMUX Immunic	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/19/2026	ACHV Achieve Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/19/2026	COLL Collegium Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$56.00 ➝ $48.00
8/17/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$18.00 ➝ $14.00
8/13/2026	ACHV Achieve Life Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/12/2026	ACHV Achieve Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$18.00
8/12/2026	ACHV Achieve Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	ACHV Achieve Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/11/2026	COLL Collegium Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	($0.14) per share	N/A
COLL Collegium Pharmaceutical	$808.21M	0.95	$15.08 per share	1.56	$9.58 per share	2.46
IMUX Immunic	N/A	N/A	N/A	N/A	$9.35 per share	N/A
PHAT Phathom Pharmaceuticals	$239.66M	3.21	N/A	N/A	($4.26) per share	-2.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.55	N/A	N/A	N/A	N/A	-511.12%	-82.35%	11/5/2026 (Estimated)
COLL Collegium Pharmaceutical	$62.87M	$1.24	18.98	4.16	N/A	5.93%	91.43%	15.57%	11/5/2026 (Estimated)
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	8.19	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)

Latest IMUX, ACHV, COLL, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ACHV Achieve Life Sciences	-$0.1649	-$0.80	-$0.6351	-$0.80	N/A	N/A
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
8/6/2026	Q2 2026	COLL Collegium Pharmaceutical	$1.72	$1.92	+$0.20	-$0.46	$199.63 million	$199.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	0.95	0.95
COLL Collegium Pharmaceutical	3.32	1.03	0.84
IMUX Immunic	N/A	5.05	5.05
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
COLL Collegium Pharmaceutical	N/A
IMUX Immunic	51.82%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
COLL Collegium Pharmaceutical	1.85%
IMUX Immunic	5.49%
PHAT Phathom Pharmaceuticals	9.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	102.90 million	101.05 million	Optionable
COLL Collegium Pharmaceutical	210	32.56 million	31.95 million	Optionable
IMUX Immunic	70	13.64 million	12.90 million	Optionable
PHAT Phathom Pharmaceuticals	110	80.90 million	73.35 million	Optionable

IMUX, ACHV, COLL, and PHAT Headlines

Recent News About These Companies

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

4,525,129 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by BlackRock Inc.

September 1, 2026 | marketbeat.com

Hsbc Holdings PLC Purchases Shares of 709,695 Phathom Pharmaceuticals, Inc. $PHAT

August 29, 2026 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2% - What's Next?

August 20, 2026 | marketbeat.com

3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc.

August 18, 2026 | marketbeat.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 17, 2026 | marketbeat.com

Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth

August 15, 2026 | tipranks.com

Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT

August 11, 2026 | marketbeat.com

Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT

August 9, 2026 | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

August 4, 2026 | globenewswire.com

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

August 3, 2026 | businesswire.com

Phathom Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 1, 2026 | seekingalpha.com

Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4

August 1, 2026 | seekingalpha.com

PHAT stock clocks worst day in over 1.5 years — what sparked the selloff?

July 30, 2026 | msn.com

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Phathom Pharmaceuticals (PHAT) Q2 2026 Earnings

July 30, 2026 | 247wallst.com

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

July 30, 2026 | prnewswire.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

July 30, 2026 | zacks.com

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026 | globenewswire.com

Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q2 2026 Result

July 29, 2026 | finance.yahoo.com

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business ...

July 20, 2026 | caledonianrecord.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMUX, ACHV, COLL, and PHAT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$8.49 +0.18 (+2.17%)

As of 09/4/2026 04:00 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Collegium Pharmaceutical NASDAQ:COLL

$23.53 -0.17 (-0.72%)

As of 09/4/2026 04:00 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Immunic NASDAQ:IMUX

$13.11 +0.35 (+2.74%)

As of 09/4/2026 04:00 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.50 +0.45 (+4.97%)

As of 09/4/2026 04:00 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMUX, ACHV, COLL, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMUX, ACHV, COLL, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMUX, ACHV, COLL, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMUX, ACHV, COLL, and PHAT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Collegium Pharmaceutical NASDAQ:COLL

Immunic NASDAQ:IMUX

Phathom Pharmaceuticals NASDAQ:PHAT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMUX, ACHV, COLL, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMUX, ACHV, COLL, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMUX, ACHV, COLL, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMUX, ACHV, COLL, and PHAT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Collegium Pharmaceutical NASDAQ:COLL

Immunic NASDAQ:IMUX

Phathom Pharmaceuticals NASDAQ:PHAT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools